New drug cocktail targets tough colorectal cancers

NCT ID NCT06369259

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of three drugs—avutometinib, defactinib, and cetuximab—can help control advanced colorectal cancer that has stopped responding to standard anti-EGFR treatment. About 33 participants will receive the drugs orally and intravenously. The main goal is to check safety and see if the cancer shrinks or stabilizes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avutometinib, defactinib, and cetuximab
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced colorectal cancer that no longer responds to standard anti-EGFR therapy.
What could go wrong: This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The drug combination may cause side effects and may not control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED COLORECTAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77807, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.